Category Press Releases

Xeris

Xeris Secures Orange Book Listing for U.S. Patent on Recorlev®XerisXeris Secures Orange Book Listing for U.S. Patent on Recorlev®

Xeris Biopharma Strengthens Long-Term Market Position with Orange Book Listing of New U.S. Patent for Recorlev® Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly expanding biopharmaceutical company focused on developing and commercializing innovative treatments to address complex and underserved medical…

Read MoreXeris Secures Orange Book Listing for U.S. Patent on Recorlev®XerisXeris Secures Orange Book Listing for U.S. Patent on Recorlev®

BeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal

BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biotechnology company, announced a significant financial and strategic transaction involving…

Read MoreBeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal

Quanterix Accelerator Lab Secures Prestigious New York State Clinical Laboratory Permit

Quanterix Accelerator Laboratory Secures New York State Clinical Laboratory Permit, Expanding Biomarker Research and Clinical Testing Capabilities Nationwide Quanterix Corporation (NASDAQ: QTRX), a biotechnology company recognized for revolutionizing precision medicine through its ultrasensitive biomarker detection platforms, today announced a major…

Read MoreQuanterix Accelerator Lab Secures Prestigious New York State Clinical Laboratory Permit
Altasciences

Altasciences Selected by Steel Therapeutics to Lead Pivotal Toxicology Study for Fizurex™

Altasciences Chosen by Steel Therapeutics to Advance Pivotal Toxicology Study for Fizurex™ Altasciences, a leading provider of integrated drug development solutions, announced that it has been selected by Steel Therapeutics, Inc. (“Steel”) to initiate a pivotal toxicology study for Fizurex™,…

Read MoreAltasciences Selected by Steel Therapeutics to Lead Pivotal Toxicology Study for Fizurex™

Circle Pharma Publishes Nature Study on Novel Cancer Therapy

Circle Pharma’s Nature Publication Highlights Breakthrough in Cyclin A/B RxL Inhibition and Preclinical Anti-Tumor Activity Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, announced the publication of a landmark paper in Nature detailing…

Read MoreCircle Pharma Publishes Nature Study on Novel Cancer Therapy

Nuvem Expands Leadership to Advance Pharmacy Service Model

Nuvem Expands Leadership Team to Accelerate Pharmacy Service Model for Community Health Providers Strengthened product, technology, and finance leadership positions company to scale mission-driven pharmacy solutions Nuvem, a leading tech-enabled pharmacy services company dedicated to empowering community health providers, today…

Read MoreNuvem Expands Leadership to Advance Pharmacy Service Model